The Division of Clinical Pharmacology at the Indiana University School of Medicine was established in 1986 and a training grant was first funded in 1992. It was most recently funded in 1997 for 5 years with two fellowship slots in the first year and three in years 2 through 5. Since its inception, the program has had a sufficient number of applicants to not only fill the training grant slots with qualified applicants, but to allow the acceptance of additional trainees that we have been able to fund from other sources. During the last cycle the program has continued to attract excellent applicants and a series of productive fellows have graduated. During the last cycle there have been a number of significant changes in the University environment that significantly improve the training environment for the current application. These include a new Clinical Scientist Research Training Award to the Department of Medicine, a new and invigorated Bioethics program, and a 5100 million genomics initiative: (the INOEN award), all of which create a notably' richer and deeper training environment for our fellows. The arrival of three new core training faculty from a T32-funded training environment at Georgetown University will also notably expand and improve training through the addition of a significant pharmacogenetic component to the already nationally competitive training in clinical pharmacokinetics, informatics and clinical research. The objective of this program is to train physicians in research-oriented academic clinical pharmacology. This training encompasses a minimum of two years and is designed to generate independent investigators for careers in research, government and industry. The demand for non-physician clinical pharmacologists is substantial and therefore Ph.D. and Pharm. D. applicants are also considered. The research activities include programs in drug metabolism, pharmacokineties, pharmaeodynamies, pharmacogeneties, pharmacoepidemiology and clinical study design. Didactic exercises include courses in drug metabolism, pharmacokinetics, study design, biostatistics, and ethics of scientific research and principles of clinical pharmacology. Research seminars include weekly seminars in this Division and the numerous medical subspecialty programs at this large medical center. A weekly clinical pharmacology journal club and principles in clinical pharmacology discuss a wide variety of clinical pharmacology issues.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM008425-11
Application #
6554676
Study Section
Special Emphasis Panel (ZGM1-BRT-2 (PD))
Program Officer
Okita, Richard T
Project Start
1992-07-01
Project End
2008-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
11
Fiscal Year
2003
Total Cost
$173,430
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Kanuri, Sri H; Ipe, Joseph; Kassab, Kameel et al. (2018) Next generation MicroRNA sequencing to identify coronary artery disease patients at risk of recurrent myocardial infarction. Atherosclerosis 278:232-239
Eadon, Michael T; Kanuri, Sri H; Chapman, Arlene B (2018) Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment. Expert Rev Precis Med Drug Dev 3:33-47
Gufford, Brandon T; Robarge, Jason D; Eadon, Michael T et al. (2018) Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes. Pharmacol Res Perspect 6:e00386
Burgess, Kimberly S; Ipe, Joseph; Swart, Marelize et al. (2018) Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs. Clin Pharmacol Ther 104:130-138
Levy, Kenneth D; Blake, Kathryn; Fletcher-Hoppe, Colette et al. (2018) Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. Genet Med :
Fulton, Cathy R; Swart, Marelize; De Luca, Thomas et al. (2018) Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness. J Nurse Pract 14:697-704.e1
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Pierson, Rebecca C; Gufford, Brandon T; Desta, Zeruesenay et al. (2017) Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics 18:835-841
Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:

Showing the most recent 10 out of 116 publications